Search
State of Possible: Kymera Therapeutics Founder and CEO Nello Mainolfi talks protein degradation, his take on recent industry data, and updates on the company's programs, including a new one to come
He gives a brief overview of this approach, comments on recent competitor data in cancer, and highlights Kymera's STAT6 and TYK2 programs.
Mar 26
Nello Mainolfi shares an update on Kymera and the progress of the protein degradation field
He gives updates on programs such as IRAK4, STAT6, TYK2, and STAT3, and describes learnings in protein degradation that Kymera has...
Aug 9, 2024
Kymera shows us the technologies that enable the development of protein degradation based medicines
Nello Mainolfi explains the concept of protein degradation and describes three key technologies that enable precision protein measurement.
Aug 7, 2023
.png){kind=logo}
